A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts

L G Brown; S K Wegner; H Wang; K R Buhler; E W Arfman; P H Lange; R L Vessella

doi:10.1038/sj.pcan.4500233

A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts

Prostate Cancer Prostatic Dis. 1998 Jun;1(4):208-215. doi: 10.1038/sj.pcan.4500233.

Authors

L G Brown¹, S K Wegner, H Wang, K R Buhler, E W Arfman, P H Lange, R L Vessella

Affiliation

¹ Department of Urology, University of Washington, Seattle, WA 98195, USA.

PMID: 12496897
DOI: 10.1038/sj.pcan.4500233

Abstract

Monoclonal antibodies with high specificity for prostate tissue are of interest for prostate cancer research and treatment. Reactivity and specificity of a new murine monoclonal antibody, 107-1A4, was assessed by immunohistochemistry, ELISA and indirect immunofluorescence (IDIF). 107-1A4 stained all normal and malignant prostate tissue specimens while reactivity to non-prostate tissue was limited to the tubules of the normal kidney and renal cell carcinoma. Twenty two human cell lines were included in the reactivity survey; only the immunogen prostate cancer line LNCaP reacted with 107-1A4. Seminal plasma proteins PSA, PAP, PSMA, and PSP-94 were determined not to be the 107-1A4 antigen.